Dr Oliver Van Oekelen talks to ecancer about his study looking at the suboptimal humoral immune response to COVID-19 vaccination in myeloma patients.
He reports that the study found that myeloma patients mound a variable and suboptimal immune response after receiving two doses of an mRNA COVID-19 vaccine.
Dr Van Oekelen also reports that over 50% of patients had no detectable antibodies at all.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.